2681 - 2690 of 7915 Results
Title
Year
- Novel Approach to Movement Disorder Society–Unified Parkinson's Disease Rating Scale Monitoring in Clinical Trials: Longitudinal Item Response Theory Models2021OPENTitle: Novel Approach to Movement Disorder Society–Unified Parkinson's Disease Rating Scale Monitoring in Clinical Trials: Longitudinal Item Response Theory ModelsJournal Name: Movement Disorders Clinical PracticePublisher: WileyVol: 8Issue #: 7Start Page: 1083End Page: 1091Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1002/mdc3.13311Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/mdc3.13311Citation Count: 7
- Pharmacological rescue of impaired mitophagy in Parkinson’s disease-related LRRK2 G2019S knock-in mice2021OPENTitle: Pharmacological rescue of impaired mitophagy in Parkinson’s disease-related LRRK2 G2019S knock-in miceJournal Name: eLifePublisher: eLife Sciences Publications, LtdVol: 10Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-by, cc-byDOI - Digital Object Identifier: 10.7554/elife.67604Best OA location URL: https://doi.org/10.7554/elife.67604Citation Count: 72
- Sex differences in brain atrophy and cognitive impairment in Parkinson’s disease patients with and without probable rapid eye movement sleep behavior disorder2021OPENTitle: Sex differences in brain atrophy and cognitive impairment in Parkinson’s disease patients with and without probable rapid eye movement sleep behavior disorderJournal Name: Journal of NeurologyPublisher: Springer Science and Business Media LLCVol: 269Issue #: 3Start Page: 1591End Page: 1599Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1007/s00415-021-10728-xBest OA location URL: https://link.springer.com/content/pdf/10.1007/s00415-021-10728-x.pdfCitation Count: 25
- Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders2021OPENTitle: Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disordersJournal Name: Journal of Neurology, Neurosurgery & PsychiatryPublisher: BMJVol: 93Issue #: 1Start Page: 24End Page: 31Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1136/jnnp-2021-326904Best OA location URL: https://hal.sorbonne-universite.fr/hal-03471111/documentCitation Count: 79
-
OPENTitle: Assessing the Quality and Reliability of COVID-19 Information on Patient Organization WebsitesJournal Name: Frontiers in CommunicationPublisher: Frontiers Media SAVol: 6Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3389/fcomm.2021.716683Best OA location URL: https://www.frontiersin.org/articles/10.3389/fcomm.2021.716683/pdfCitation Count: 7
- Discovery of the First Selective M4 Muscarinic Acetylcholine Receptor Antagonists with in Vivo Antiparkinsonian and Antidystonic Efficacy2021RESTRICTEDTitle: Discovery of the First Selective M4 Muscarinic Acetylcholine Receptor Antagonists with in Vivo Antiparkinsonian and Antidystonic EfficacyJournal Name:Publisher:Vol:Issue #:Start Page: 1306End Page: 1321Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1021/acsptsci.0c00162;Citation Count: 9
- Discovery of the First Selective M4 Muscarinic Acetylcholine Receptor Antagonists with in Vivo Antiparkinsonian and Antidystonic Efficacy2021OPENTitle: Discovery of the First Selective M4 Muscarinic Acetylcholine Receptor Antagonists with in Vivo Antiparkinsonian and Antidystonic EfficacyJournal Name: ACS Pharmacology & Translational SciencePublisher: American Chemical Society (ACS)Vol: 4Issue #: 4Start Page: 1306End Page: 1321Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1021/acsptsci.0c00162Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369681Citation Count: 13
- Disentangling the PIGD classification for the prediction of cognitive impairment in de novo Parkinson’s disease2021OPENTitle: Disentangling the PIGD classification for the prediction of cognitive impairment in de novo Parkinson’s diseaseJournal Name: Journal of NeurologyPublisher: Springer Science and Business Media LLCVol: 269Issue #: 3Start Page: 1566End Page: 1573Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1007/s00415-021-10730-3Best OA location URL: https://link.springer.com/content/pdf/10.1007/s00415-021-10730-3.pdfCitation Count: 6
-
OPENTitle: Modeling Sporadic Alzheimer's Disease in Human Brain Organoids under Serum ExposureJournal Name: Advanced SciencePublisher: WileyVol: 8Issue #: 18Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1002/advs.202101462Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/advs.202101462Citation Count: 95
-
RESTRICTEDTitle: Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2021 UpdateJournal Name: Journal of Parkinson's DiseasePublisher: IOS PressVol: 11Issue #: 3Start Page: 891End Page: 903Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-by-ncDOI - Digital Object Identifier: 10.3233/jpd-219006Best OA location URL: https://content.iospress.com:443/download/journal-of-parkinsons-disease/jpd219006?id=journal-of-parkinsons-disease%2Fjpd219006Citation Count: 47